Phase I/II triple therapy study of umbralisib and ublituximab ("U2") combined with checkpoint inhibition in patients with rel/ref CLL and Richter's transformationAnthony Mato,Jakub Svoboda,Eline Luning-Prak,Steven Schuster,Patricia Tsao,Colleen Dorsey,Lisa Sarmasti,Pamela Becker,Danielle Brander,Mark Geyer,Jae Park, Jr. Deonarine Isaac,Cara King,Beth Morrigan, Jill Elwell,Kaitlin Kennard,Lindsey Roeker,Andrew Zelenetz,Michelle Purdom,Dana Paskalis, Peter Sportelli,Hari Miskin,Michael Weiss,Mazyar ShadmanLEUKEMIA & LYMPHOMA(2020)引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要